A recent study indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt traditional lifestyle plans.
Findings released in a prominent medical journal demonstrates that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing such drugs should be informed of the danger of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The study, which looked at dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Scientists point out that individuals who lose weight through dieting generally have a slower creep back—around 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Experts suggest the mechanism of the drugs explains the amplified weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels several times higher than normal may cause the body to produce less of its own natural hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
The NHS advise the injections for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, given the likelihood of relapse, the treatment might need to be life-long.
This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like hypertension.
Patient Accounts
People who have discontinued the medication explain a intense resurgence of hunger.
"It felt as if a switch that goes on and I was suddenly extremely hungry," said a patient.
This difficulty is compounded if users have not adopted sustainable lifestyle or habit changes during treatment.
Widespread Use
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is higher among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, researchers stress that while these medications are effective tools for shedding pounds, they are not a magic cure and lasting health benefits hinges on ongoing behavioural management.
